Kerri Fitzgerald

DocwireNews

Here are the top stories covered by DocWire News this week in the Hematology &amp; Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved various new therapies, a study assessed thyroid cancer surveillance in post-9/11 first responders, and more.<a href="https://www.docwirenews.com/hematology-oncology/rapid-and-repetitive-covid-19-testing-needed-for-cancer-care/">Treatment for cancer patients in the United Kingdom</a> has been stopped or delayed due to COVID-19. In a press release, Cancer Research UK has called for widespread testing in the cancer patient population.<a href="https://www.docwirenews.com/hematology-oncology/the-role-of-medical-surveillance-in-increased-post-9-11-thyroid-cancer-in-world-trade-center-exposed-workers/">A new study examined whether there is a correlation between medical surveillance</a> and incidence of post-Sept. 11, 2001,&nbsp;thyroid cancer among World Trade Center-exposed firefighters and emergency medical service workers. They also explored differences between asymptomatic and symptomatic cases.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-breast-cancer-treatment-through-international-approval-pathway/">The FDA approved Tukysa&trade;</a> (tucatinib) in combination with trastuzumab and capecitabine for the treatment of advanced human epidermal growth factor receptor 2-positive&nbsp;breast cancer&nbsp;that is unresectible or has spread to other parts of the body, including the brain, and who have received one or more prior treatments. This is the first new drug approved under&nbsp;Project Orbis, an international collaboration.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-first-targeted-treatment-for-rare-bile-duct-cancer/">The FDA approved Pemazyre&trade;</a> (pemigatinib), the first targeted treatment for adults with certain types of previously treated advanced&nbsp;cholangiocarcinoma, a rare form of cancer that forms in&nbsp;bile ducts. The oral kinase inhibitor is approved for patients with tumors with the&nbsp;FGFR2&nbsp;gene, which occur in about 9% to 14%&nbsp;of this patient population.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-new-treatment-for-aggressive-breast-cancer/">The FDA approved Trodelvy&trade;</a> (sacituzumab govitecan-hziy) for patients with metastatic triple-negative&nbsp;breast cancer&nbsp;who have received at least two prior treatments.In case you missed it, more hem/onc headlines are featured below:<ul>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/less-pediatric-cancer-patients-enrolling-in-clinical-study-shows/">Less Pediatric Cancer Patients Enrolling in Clinical, Study Shows</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/acupuncture-may-improve-cognitive-function-in-insomniac-cancer-survivors/">Acupuncture May Improve Cognitive Function in Insomniac Cancer Survivors</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/early-gp-referrals-lead-to-cancer-patients-living-longer-study-finds/">Early General Practitioner Referrals Lead to Cancer Patients Living Longer, Study Finds</a></li>
</ul>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Hem/Onc Roundup: COVID-19 Testing Needed for Patients with Cancer, FDA Approvals, and more

Oncology

Here are the top stories covered by DocWire News this week in the Hematology &amp; Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved various ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe